Midline Catheters: The Complete Clinical Reference

The midline catheter is the fastest-growing vascular access device in acute and post-acute care. Sitting between the short peripheral IV and the PICC on the device spectrum, a midline delivers reliable, lower-risk peripheral access for the large population of patients who need dependable venous access for one to four weeks but do not require — and should not be exposed to the risks of — a central line.

This is the department reference for midline catheters: what a midline is, who should (and should not) get one, how it is inserted and maintained, its complication profile, how long it can stay in, how it is removed, and how to choose between a midline and a PICC. Use the linked guides for deeper dives on insertion technique, complications, and infusion safety.

Parent reference: Vascular Access: Complete Clinical Reference · Compare: PICC vs Midline

What Is a Midline Catheter?

A midline catheter is a peripheral vascular access device, typically 8–25 cm in length, inserted via the basilic, cephalic, or brachial vein in the upper arm, with the catheter tip advanced only to the level of the axillary vein at or distal to the axilla — proximal to the shoulder but not in the central venous system.

The defining characteristic is the tip location: it remains peripheral. This single fact drives every clinical implication of the device:

• It is governed by the limits of peripheral infusion (osmolarity, pH, vesicant status).
• It does not require chest radiography for tip confirmation.
• It carries a lower bloodstream-infection risk than central catheters because it is not a central line (a midline-associated bloodstream infection is not counted as a CLABSI under NHSN definitions).

A midline is sometimes called an extended dwell peripheral catheter, although that term is also used loosely for shorter 6–15 cm “long peripheral” catheters. In current standards, a midline is specifically a single- or dual-lumen catheter whose tip lies at or near the axilla.

Where the Midline Sits on the Device Spectrum

See the full Vascular Access Device Spectrum on the department hub and the side-by-side Vascular Access Devices Compared matrix.

Indications

A midline is the right device when all of the following are true: the therapy is expected to last roughly 5 days to 4 weeks, the infusate is compatible with peripheral administration, and the patient has (or is at risk for) difficult peripheral access that would otherwise require repeated short-PIV restarts.

Common appropriate uses:

• Intravenous antibiotics that are peripherally compatible (the most common indication)
• Hydration and electrolyte replacement
• Difficult intravenous access (high DIVA score) needing reliable medium-term access
• Antiemetics, analgesics, and other non-vesicant medications
• Blood sampling in patients with poor peripheral veins (program-dependent)
• A peripheral-compatible bridge while central-line need is being determined

The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC) supports the midline as the preferred device for peripherally-compatible infusions of 6–14 days, and increasingly beyond, in preference to a PICC, to preserve central veins and avoid central-line risk.

Contraindications and Limitations

Because the tip is peripheral, a midline must not be used for therapies that require central dilution:

• Continuous vesicant chemotherapy (risk of catastrophic extravasation)
• Parenteral nutrition (TPN/PPN with high dextrose concentration)
• Solutions with osmolarity > ~900 mOsm/L
• Sustained infusions with pH < 5 or > 9
• Continuous vasopressors (central access preferred)

Relative cautions:

• Chronic kidney disease / anticipated dialysis — preserve upper-arm and forearm veins for future arteriovenous fistula creation (consult nephrology; follow vessel-preservation policy).
• History of thrombosis or hypercoagulable state — midlines carry a measurable thrombosis risk.
• Known central venous stenosis or SVC syndrome.

See Evidence-Based Device Selection and Infusion Therapy Safety for osmolarity and pH thresholds.

Insertion

Midlines are placed at the bedside by a trained inserter (vascular access nurse, IV team, or credentialed clinician) using ultrasound guidance and, in most programs, a modified Seldinger technique (MST).

1. Vein selection. Under ultrasound, select the basilic vein (preferred — straightest path, away from the brachial artery and median nerve), or the brachial or cephalic vein, in the mid-to-upper arm. Apply the rule of choosing a vein whose diameter is large enough that the catheter occupies no more than one-third of the lumen, to reduce thrombosis risk.
2. Sterile technique. Maximal aseptic preparation: hand hygiene, skin antisepsis with 2% CHG in 70% alcohol (full dry time), and a sterile field.
3. Anesthetize and access. Infiltrate local anesthetic; access the vein under real-time ultrasound.
4. Advance via MST. Thread the guidewire, make a small skin nick, advance the introducer/dilator, then thread the catheter to the predetermined length so the tip lies at the axillary vein.
5. Confirm and secure. Confirm brisk blood return and easy flush. No chest X-ray is required. Secure with an engineered securement device and a sterile transparent dressing; document insertion length and external length.

For ultrasound technique, vein assessment, and MST detail, see Ultrasound-Guided Vascular Access.

Care and Maintenance

Midline maintenance mirrors central-line maintenance discipline even though the device is peripheral:

• Flush and lock with the SASH/SAS sequence — Saline, Administer medication, Saline, (Heparin only if institutionally required; many midlines are saline-locked). Use a 10 mL-diameter syringe and pulsatile flush to clear the lumen. See Flushing and Locking: The SASH Protocol.
• Scrub the hub with alcohol or CHG for 15 seconds and allow to dry before every access.
• Dressing changes with a sterile transparent semipermeable dressing every 7 days and whenever it is loose, soiled, or damp. See Dressing Change Procedure.
• Assess each shift for the VIP (Visual Infusion Phlebitis) score, upper-arm tenderness or swelling, external catheter length (for migration), blood return, and continued need.
• Document daily the assessment and the ongoing indication; remove the line as soon as it is no longer needed.

Complications

The midline complication profile differs from both PIVs and PICCs.

The single most important safety principle: never give a midline-incompatible drug through a midline. For complication workups (alteplase dosing, DVT management, extravasation), see Catheter Complications.

Dwell Time and Removal

A midline is intended for 1–4 weeks of therapy. Current evidence and standards support an indication-based rather than a fixed-time removal: keep a well-functioning, asymptomatic midline in place for the duration of the prescribed therapy, reassess the need daily, and remove it promptly for complications. Many institutions set a routine outer dwell limit around 28 days and require documented justification beyond that.

Removal is simple: explain the procedure, position the arm, remove the dressing and securement, withdraw the catheter with steady gentle traction, inspect the catheter for completeness and measure the tip-to-hub length, and apply firm pressure until hemostasis with a sterile dressing. Document removal, catheter integrity, and site condition.

Midline vs PICC: How to Choose

The decision turns on three questions: what is being infused, how long is it needed, and what is the patient’s vascular and clinical context.

• Choose a midline when the infusate is peripherally compatible and the duration is roughly 1–4 weeks. The midline avoids central-line risk (CLABSI, central thrombosis), needs no chest X-ray, and preserves central veins.
• Choose a PICC when the therapy includes vesicants, TPN, high-osmolarity or extreme-pH solutions, vasopressors, or will exceed several weeks, or when reliable central access and central pressure monitoring are required.

The full decision matrix, with osmolarity/pH thresholds and worked examples, is in PICC vs Midline and PICC vs Midline vs CVC.

Special Populations

• Oncology: acceptable for non-vesicant supportive therapy and hydration, but not for continuous vesicant chemotherapy — see Vascular Access in Oncology.
• Pediatrics/NICU: smaller-gauge midlines are used selectively; vein size and thrombosis risk are limiting — see NICU and Pediatric Vascular Access.
• CKD: practice vessel preservation; avoid using upper-arm veins that may be needed for future fistula access.
• OPAT (outpatient parenteral antibiotics): midlines are increasingly first-line for short-course peripherally-compatible OPAT.

Quality and Safety Metrics

High-performing midline programs track:

• First-stick success rate (target ≥90% with ultrasound)
• Midline thrombophlebitis rate (per 1,000 catheter-days)
• Catheter-related thrombosis rate
• Premature removal rate and reasons
• Vesicant/incompatible-infusion safety events (target: zero)
• Dwell time vs. therapy completion (right device, right duration)

Explore the Midline Library

• PICC vs Midline: Device Selection
• Ultrasound-Guided Vascular Access
• Catheter Complications: Recognition and Management
• Infusion Therapy Safety
• Going Home with a Midline Catheter

References

1. Gorski LA, et al. (2021). Infusion Therapy Standards of Practice (8th ed.). Journal of Infusion Nursing, 44(Suppl 1), S1–S224.
2. Chopra V, et al. (2015). The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC). Annals of Internal Medicine, 163(6 Suppl), S1–S40.
3. Adams DZ, et al. (2016). The midline catheter: a clinical review. Journal of Emergency Medicine, 51(3), 252–258.
4. Tripathi S, et al. (2021). Peripherally inserted central catheter versus midline catheter: a systematic review and meta-analysis. Journal of Vascular Access.
5. Chopra V, et al. (2018). Variation in use and outcomes related to midline catheters: results from a multicentre pilot study. BMJ Quality & Safety, 28(9), 714–720.
6. CDC/NHSN. (2023). Bloodstream Infection Event (CLABSI) — device definitions. NHSN Patient Safety Component Manual.